Literature DB >> 22290146

A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice.

Sarah Weber1, Haijun Tian, Nico van Rooijen, Liise-Anne Pirofski.   

Abstract

Antibodies to pneumococcal capsular polysaccharide (PPS) are required for PPS-based vaccine-mediated protection against Streptococcus pneumoniae. Previous work established that 1E2, a mouse IgG1 to PPS3 that does not induce serotype 3 (ST3) S. pneumoniae killing by phagocytes in vitro, protects mice from death after intranasal infection with ST3, but its efficacy was abrogated in FcγR (F common gamma receptor)-deficient mice. In this study, we determined whether 1E2 efficacy against pulmonary ST3 infection requires FcγRIII. 1E2 did not protect FcγRIII-deficient (FcγRIII(-/-)) mice. Studies of the mechanism of 1E2-mediated effects showed that it resulted in a marked reduction in lung inflammation in ST3-infected wild-type (Wt [C57BL/6]) mice that was abrogated in FcγRIII(-/-) mice. 1E2 had no effect on early bacterial clearance in the lungs of ST3-infected Wt, FcγRIIB(-/-), or FcγRIII(-/-) mice, but it reduced levels of bacteremia and serum macrophage inflammatory protein-2) (MIP-2), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in Wt and FcγRIIB(-/-) mice, strains in which it is protective. As previous work showed that neutrophils were dispensable for 1E2 efficacy, we investigated whether macrophages are required for 1E2 efficacy against intranasal infection with ST3 and found that its efficacy was abrogated in Wt mice depleted of macrophages intranasally. In vitro studies revealed that1E2 promoted ST3 internalization by naïve alveolar macrophages but did not induce early intracellular killing. Macrophages from 1E2-treated ST3-infected mice studied ex vivo exhibited more apoptosis than those from FcγRIII(-/-) mice. These findings suggest that 1E2 mediates protection against ST3 in mice by affecting the inflammatory response, perhaps in part via macrophage apoptosis, rather than by inducing early bacterial clearance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290146      PMCID: PMC3318404          DOI: 10.1128/IAI.06081-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin.

Authors:  Kyung-Hyun Park-Min; Natalya V Serbina; Wentian Yang; Xiaojing Ma; Gerald Krystal; Benjamin G Neel; Stephen L Nutt; Xiaoyu Hu; Lionel B Ivashkiv
Journal:  Immunity       Date:  2007-01       Impact factor: 31.745

2.  Effect of concentrated ambient particles on macrophage phagocytosis and killing of Streptococcus pneumoniae.

Authors:  Hongwei Zhou; Lester Kobzik
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

3.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 4.  Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Authors:  Sandra Romero-Steiner; Carl E Frasch; George Carlone; Roland A Fleck; David Goldblatt; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 5.  Pathogenesis of pneumococcal pneumonia.

Authors:  R Novak; E Tuomanen
Journal:  Semin Respir Infect       Date:  1999-09

6.  Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.

Authors:  Tamika Burns; Maria Abadi; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia.

Authors:  Helen M Marriott; Paul G Hellewell; Simon S Cross; Paul G Ince; Moira K B Whyte; David H Dockrell
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

8.  Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.

Authors:  Isabelle Henckaerts; Nathalie Durant; Dany De Grave; Lode Schuerman; Jan Poolman
Journal:  Vaccine       Date:  2006-09-20       Impact factor: 3.641

9.  The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection.

Authors:  Bing Ren; Mark A McCrory; Christina Pass; Daniel C Bullard; Christie M Ballantyne; Yuanyuan Xu; David E Briles; Alexander J Szalai
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

Review 10.  The antiinflammatory activity of IgG: the intravenous IgG paradox.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2007-01-16       Impact factor: 14.307

View more
  22 in total

Review 1.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

Review 2.  Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing.

Authors:  J D Aberdein; J Cole; M A Bewley; H M Marriott; D H Dockrell
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

3.  Help is on the way: Monoclonal antibody therapy for multi-drug resistant bacteria.

Authors:  Rachelle Babb; Liise-Anne Pirofski
Journal:  Virulence       Date:  2017-03-17       Impact factor: 5.882

4.  The promised land of human immunology.

Authors:  Laura F Su; Arnold Han; Helen M McGuire; David Furman; Evan W Newell; Mark M Davis
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2014-03-17

5.  PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism.

Authors:  Jerome T McKay; Ryan P Egan; Rama D Yammani; Lieping Chen; Tahiro Shin; Hideo Yagita; Karen M Haas
Journal:  J Immunol       Date:  2015-01-26       Impact factor: 5.422

6.  A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice.

Authors:  Christopher R Doyle; Jee-Young Moon; Johanna P Daily; Tao Wang; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

7.  Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.

Authors:  Fernanda A Lima; Daniela M Ferreira; Adriana T Moreno; Patrícia C D Ferreira; Giovana M P Palma; Jorge M C Ferreira; Isaias Raw; Eliane N Miyaji; Paulo L Ho; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

8.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

9.  An ahemolytic pneumolysin of Streptococcus pneumoniae manipulates human innate and CD4⁺ T-cell responses and reduces resistance to colonization in mice in a serotype-independent manner.

Authors:  M Nadeem Khan; John Robert Coleman; Joshua Vernatter; Avanish Kumar Varshney; Chad Dufaud; Liise-Anne Pirofski
Journal:  J Infect Dis       Date:  2014-06-13       Impact factor: 5.226

Review 10.  Current concepts in host-microbe interaction leading to pneumococcal pneumonia.

Authors:  Joshua Vernatter; Liise-anne Pirofski
Journal:  Curr Opin Infect Dis       Date:  2013-06       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.